Therapix Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update
THX-110 is a combination drug candidate for the treatment of Tourette syndrome, Obstructive Sleep Apnea and pain. It is composed of two components: (1) dronabinol (an FDA approved analog of ∆9-tetrahydracannabinol, or "THC"), and (2) palmitoylethanolamide ("PEA"), which is an endogenous fatty acid amide that belongs to the class of nuclear factor agonists, which are molecules that regulate the expression of genes. The combination of THC and PEA may induce a reaction known as the "Entourage Effect". The basic tenet of the entourage effect is that cannabinoids work together, or possess synergy, and affect the body in a mechanism similar to the body's own endocannabinoid system, which is a group of molecules and receptors in the brain that mediates the psychoactive effects of cannabis. This entourage effect may account for the pharmacological actions of PEA. Based on an activity enhancement of other physiological compounds, PEA may indirectly stimulate the cannabinoid receptors by potentiating their affinity for a receptor or by inhibiting their metabolic degradation, and by doing so, may increase the uptake of cannabinoid compounds, such as THC. Thus, it is speculated that the presence of the PEA molecule could increase the efficacy of THC, while reducing the required dosage and decreasing associated deleterious adverse events.
About THX-130:
THX-130 is a
proprietary, innovative, formulation of ultra-low dose dronabinol,
which is intended to provide a treatment for Mild Cognitive
Impairment (MCI). Recent pre-clinical animal studies have found
that an ultra-low dose of THC could potentially protect the brain
from long-term cognitive impairment, which may be caused by aging,
lack of oxygen supply, seizures or use of drugs. Certain
pre-clinical studies also suggest that ultra-low doses of THC cause
animals to improve performance in behavioral tests that measure
learning and memory.
About THX-150:
THX-150 is a drug
candidate intended for the treatment of infectious diseases. It
consists of dronabinol or dronabinol with PEA and a selected
antibacterial agent, which possesses antimicrobial synergy
potential.
About THX-160:
THX-160 is a drug
candidate intended for the treatment of pain. It consists of a CB2
receptor agonist with or without the opioid.
Forward-Looking Statements:
This
press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995 and other Federal securities laws.
Because such statements deal with future events and are based on
Therapix's current expectations, they are subject to various risks
and uncertainties and actual results, performance or achievements
of Therapix could differ materially from those described in or
implied by the statements in this press release. For example,
forward-looking statements include statements regarding the
Company's plans with respect to its clinical trials and its intent
to report material developments and information regarding such
trials. In addition, historic results of scientific research and
clinical and preclinical trials do not guarantee that the
conclusions of future research or trials will suggest identical or
even similar conclusions. The forward-looking statements contained
or implied in this press release are subject to other risks and
uncertainties, including those discussed under the heading "Risk
Factors" in Therapix Biosciences Ltd.'s Annual Report on Form 20-F
filed with the Securities and Exchange Commission (SEC) on
April 30, 2018 and in subsequent filings with the SEC.
Except as otherwise required by law, Therapix disclaims any
intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether
as a result of new information, future events or circumstances or
otherwise.
For further information:
Oz Adler,
CFO
Oz@therapixbio.com
Investor
Contact:
Investor Relations
IR@therapixbio.com